Ciglitazone is a PPARγ agonist. It is known to decrease insulin levels, VEGF production and blood pressure and induces cell cycle arrest in stomach cancer cells. References: Shin SJ, Kim JY, Kwon SY, Mun KC, Cho CH, Ha E. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1. Eur J Pharmacol. 2014 Nov 15;743:17-23. doi: 10.1016/j.ejphar.2014.09.013. Epub 2014 Sep 21. PubMed PMID: 25240713.

纯度：≥98%

CAS：74772-77-3